EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, hibiscus acid was reported as a nutraceutical approach for the treatment of chronic myelogenous leukemia due to protein response observed by activation of eIF2α/ATF4 pathway that induced cell cycle arrest at G2/M phase and DNA fragmentation in leukemia K562 cells [31].